Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression (DEMPROG)
|ClinicalTrials.gov Identifier: NCT01642420|
Recruitment Status : Unknown
Verified September 2012 by Malene Schjønning Nielsen, Roskilde County Hospital.
Recruitment status was: Recruiting
First Posted : July 17, 2012
Last Update Posted : September 13, 2012
Alzheimers disease (AD) is the most common course of cognitive decline and thereby the course of more than half of all cases of dementia. A proper AD diagnosis is rested on a number of examinations and tests, which combined can make AD diagnosis likely. But no single test or examination can unambiguous determine whether the patient has AD or not. Comparatively no examination or test can with accuracy predict whether a healthy person or a person with only mild cognitive (MCI)impairment in time will evolve AD.
Quantitative Electroencephalography (qEEG), cerebrospinal fluid (CSF) biomarkers, linear CT analyses and Timed Up and Go - Dual Task (TUG-DT) are relatively inexpensive and and widely available diagnostic methods, which have the potential to diagnose AD at an early stage in a reliable accurate way. But they also have the potential to predict which patients diagnosed with MCI have particular risk of developing dementia.
The purpose of the study is to investigate the relations between qEEG, CSF biomarkers, CT analyses and TUG-DT outcome and clinical features in healthy persons as well as patients with MCI and AD Furthermore to investigate whether qEEG or CSF biomarkers can predict which patients with MCI will in time evolve AD.
|Condition or disease|
|Alzheimers Disease Mild Cognitive Impairment|
|Study Type :||Observational|
|Estimated Enrollment :||115 participants|
|Observational Model:||Case Control|
|Official Title:||Quantitative Electroencephalography, Cerebrospinal Fluid Biomarkers, Linear CT Analyses and Timed Up and GO Dual Task as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression.|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||February 2017|
|Estimated Study Completion Date :||February 2017|
Mild cognitive impairment
Patients diagnosed with mild cognitive impairment
Patients diagnosed with mild Alzheimers disease
Healthy control persons
Age matched healthy persons
- Conversion from Mild Cognitive Impairment to Alzheimers disease [ Time Frame: Every year in totally of 3 years ]The primary outcome measure is progression of clinical symptoms to an extent where the formal NINCDS-ADRDA criteria for dementia is meet. The progression is based upon clinical symptoms as well as explorative determinants in form of clinical tests, CSF analysis and qEEG analysis.
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642420
|Contact: Malene s Nielsen, MD||0045 2868 email@example.com|
|Contact: Peter Høgh, MD, Ph.D||0045 4732 firstname.lastname@example.org|
|Neurologisk Afd, Roskilde Sygehus||Recruiting|
|Roskilde, Denmark, 4000|
|Principal Investigator: Malene S Nielsen, MD|
|Principal Investigator:||Malene S Nielsen, MD||Roskilde Hospital, Department of Neurology|